Pure Global
NCT06097039

Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease

Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD)
Zagazig University·ClinicalTrials.gov·device·Device trialEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
abdominal U/S
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Zagazig University
Location
Zagazig, Egypt
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2023
End date
Jan 20, 2024
Enrollment
100 participants
Primary outcome

To assess fetuin-A serum concentration,To measure liver stiffness and fibrosis degree,Number of participants with fetuin-A serum concentration and liver stiffness degree using FibroScan

Summary

The work investigate the role of fetuin-A in the diagnosis and assessment of the severity of
 non-alcoholic fatty liver disease (NAFLD).

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06097039
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06097039 through Pure Global AI's free database. This phase not specified trial is sponsored by Zagazig University and is currently Enrolling by invitation. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.